



JUNE

27

FR

# 20<sup>th</sup> Annual Meeting of the GU Medical Oncologists of Canada (GUMOC)

Friday June 27, 2025 – 08:00-16:00 ET

....

 $\bigcirc$ 

Westin Hotel, Ottawa | GOVERNOR GENERAL 1-2 | LEVEL 4



## SESSION 1 | Hot GU Topics & Crowdsourcing Solutions Moderators: Jeffrey Graham, Lori Wood

- 09:10 09:20 Which patient should we be choosing for radioligand therapy, given that it is a highly limited resource in Canada? Lillian Hanna
- 09:20 09:30 Discussion/Q&A
- 09:30 09:40 Muscle-invasive bladder cancer post Cis-Gem-Durvalumab or (in the future) EV-Pembrolizumab: What do we do with patients with complete clinical response who refuse surgery? David Maj
- 09:40 09:50 Discussion/Q&A
- 09:50 10:00 How can we leverage and work together in Canada on results of large gene sequencing panels in common and rare GU malignancies? Guliz Ozgun
- 10:00 10:10 Discussion/Q&A
- 10:10 10:30Practice Sharing across Canada<br/>Christina Canil, Neil Reaume
- 10:30 10:45 Networking Health Break

# JUNE 27 FRI

#### SESSION 2 | Radioligand Therapy in Prostate Cancer Moderators: Ali Fawaz, April Rose

- 10:45 11:05 KEYNOTE SPEAKER: How do we deliver value now and in the future for prostate cancer patients with RLT? Tanya Dorff
- 11:05 11:15 Discussion/Q&A
- 11:15 11:50 Introduction and Pre-Debate Vote PRO: In ARPI-exposed mCRPC patients, ARPI should ALWAYS be continued at the same time as Ra223 and PSMA-Lu177 Cristiano Ferrario

CON: In ARPI-exposed mCRPC patients, ARPI should NEVER be continued at the same time as Ra223 and PSMA-Lu177 Scott North

Questions, Concluding remarks and Post-Debate Vote

- 11:50 12:05 How should we develop more personalized approaches to mCSPC treatment (de)intensification? Daniel Khalaf
- 12:05 13:00 Group photo and networking lunch

### SESSION 3 | Immunotherapy and Therapeutic Targets in Prostate Cancer

#### Moderators: Urban Emmenegger, Zineb Hamilou

- 13:00 13:20 Is there a future where more patients with prostate cancer patients receive immunotherapy? Tanya Dorff
- 13:20 13:30 Discussion/Q&A
- 13:30 13:45 PARP inhibitors for prostate cancer: Few, many or all? Kim Chi
- 13:45 13:55 Discussion/Q&A
- 13:55 14:05 Can we successfully roll out T-Cell engagers programs for GU research in Canada? Michael Ong
- 14:05 14:15 Discussion/Q&A
- 14:15 14:25 Networking Health Break

	SESSION 4	The Evolving Landscape of Bladder and Kidney Cancer
<b>27</b> FRI	Moderators: Ana-Beltran Bless, Aly-Khan Lalani	
	14:25 - 14:55	Introduction and Pre-Debate Vote PRO: Platinum chemotherapy is an important option post-EV Pembro Nimira Alimohamed (10 min) CON: Platinum chemotherapy is NOT an important option post-EV Pembro Karine Tawagi (10 min)
	14:55 - 15:05	Concluding remarks and Post-Debate Vote When and how to successfully deliver FGFR inhibitors in metastatic urothelial carcinoma. Bernie Eigl
	15:05 - 15:15	Discussion/Q&A
	15:15 - 15:25	Practical Considerations for Toxicity Management of Belzutifan, Erdafitinib, and Enfortumab Maria Jiang, Ramy Saleh
	15:25 - 15:35	Discussion/Q&A
	15:35 - 16:00	GUMOC "Family" Feud Host: Rodney Breau East vs West
	16:00 - 16:30	GUMOC Business Meeting, on invitation only
		CUA Educational Session #3
	16:30 - 17:30	Prostate Cancer GOVERNOR GENERAL 1-2   LEVEL 4 *Pre-registration recommended - seats are limited.
	18:30	Private networking event for GUMOC members and faculty only.
	GOLD SPONSORS	
	AstraZeneca	
ш	Ulli Bristol Myers Squibb	
( <b>D</b>	Johnson &Johnsoi	-
		SILVER SPONSORS
		astellas MCKESSON Canada
		redited Group Learning Activity (Section 1) as defined by the Maintenance of m of the Royal College of Physicians and Surgeons of Canada, and approved

by the CUA. You may claim a maximum of 6.5 hours of credit.